Document is current
Any future updates will be listed below
-
Authors
Schraa, S. J.
van Rooijen, K. L.
van der Kruijssen, D. E. W.
Rubio Alarcón, C.
Phallen, J.
Sausen, M.
Simmons, J.
Coupé, V. M. H.
van Grevenstein, W. M. U.
Elias, S.
Verkooijen, H. M.
Laclé, M. M.
Bosch, L. J. W.
van den Broek, D.
Meijer, G. A.
Velculescu, V. E.
Fijneman, R. J. A.
Vink, G. R.
Koopman, M.
,
Dunker, Mich S.
Lutke Holzik, Martijn F.
Hoekstra, Ronald
Sommeijer, Dirkje W.
van der Bilt, Jarmila D. W.
Consten, Esther C. J.
Cirkel, Geert A.
Burghgraef, Thijs A.
van der Schans, Emma M.
Nieboer, Peter
Rietbroek, Ron C.
Dekker, Jan Willem T.
Verschoor, Arjan J.
Talsma, Koen A. K.
Brosens, Rebecca P. M.
Helgason, Helgi H.
Marinelli, Andreas W. K. S.
de Hingh, Ignace H. J. T.
Oldenhuis, Corina N.
Jansen, Jan
van Halteren, Henk K.
Stockmann, Hein B. A. C.
Beeker, Aart
Bosscha, Koop
Pruijt, Hans F. M.
Spierings, Leontine E. A. M. M.
Valkenburg-Van Iersel, Liselot B. J.
Vles, Wouter J.
de Jongh, Felix E.
van Cruijsen, Hester
Heikens, Joost T.
Zimmerman, David D. E.
van Alphen, Robert J.
Schiphorst, Anandi H. W.
van Leeuwen-Snoeks, Lobke L.
Vogelaar, Jeroen F. J.
Peters, Natascha A. J. B.
-
Funding
Funding for this research was provided by:
Healh~Hollan (LSHM19027)
ZonMW 'Personalised Medicine' program (848101011)
Dutch Digestive Foundation
Personal Genome Diagnostics
CZ Healthcare Insurance
- License Information
-
More Information
Article History
Received: 22 July 2020
Accepted: 3 August 2020
First Online: 20 August 2020
Ethics approval and consent to participate
: The study protocol, version 3.0 from February 21st 2020, is approved by the Medical Ethical Committee of the University Medical Center Utrecht, the Netherlands in March 2020 (METC nr 19/747).Any changes in the protocol will be reported to the Medical Ethical Committee.Informed verbal and written consent will be obtained for all participants at enrollment in the PLCRC cohort. Separate informed consent will be obtained for all participants randomized to the intervention arm of MEDOCC-CrEATE.
: Not applicable.
: V.E.V. is a founder of Delfi Diagnostics and Personal Genome Diagnostics, serves on the Board of Directors and as a consultant for both organizations, and owns Delfi Diagnostics and Personal Genome Diagnostics stock, which are subject to certain restrictions under university policy. Additionally, Johns Hopkins University owns equity in Delfi Diagnostics and Personal Genome Diagnostics. V.E.V. is an advisor to Bristol-Myers Squibb, Genentech, Merck, and Takeda Pharmaceuticals. Within the last five years, V.E.V. has been an advisor to Daiichi Sankyo, Janssen Diagnostics, and Ignyta. These arrangements have been reviewed and approved by the Johns Hopkins University in accordance with its conflict of interest policies. J.P. is a founder of Delfi Diagnostics and owns Delfi Diagnostics stock.
